You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201841 - 201850 of 207699 results
  1. Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

    SBC: Kadmon Corporation, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML

    SBC: P2D, INC            Topic: NCI

    DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is us ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Deimmunized TLR5 Agonist for Anticancer Therapy

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tissues in the tumor environment. Due to the scale of thisproblem and the current lack of safe and effective countermeasures against radiation toxicity, development of such agents is of broad significanc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. TRAIL Upregulation by TIC10 Analogs

    SBC: PROVID PHARMACEUTICALS INC.            Topic: NCI

    Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the lab of our collaborator, Dr. Wafik El-Deiry at Penn State University and has been shown to have preclinical efficacy in several difficult-to-treat disease settings that include unmet clinical needs su ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Synergy between MAG-1 and Cyclophosphamide for Treatment of Recurrent SCLC

    SBC: Woomera Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that a cancer -specific provasopressin antigen, called GRSA, present at the surface of these tumors will prov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Correcting Aberrant Splicing of the Human CD22 Gene

    SBC: RETROTHERAPY, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in children and adolescents. This project addresses an urgent and unmet need for the treatment of aggressive, treatment refractory BPL. Two recent studies have found a deletion of CD22 exon 12 (CD22?E12) in primary leukemic cells in the vast majority of pediatric patients with poor ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Direct RT-qPCR analysis of microRNAs in human plasma (miR-Direct)

    SBC: Somagenics, Inc.            Topic: NCI

    Our goal in this proposal is to develop a novel method for the direct detection of miRNAs in serum and plasma without requiring isolation of total RNA. Distinct expression profiles of microRNAs (miRNAs) have recently been associated with cancer and other diseases, implying that miRNAs could serve as diagnostic biomarkers for these diseases. Effective biomarkers could facilitate early detection of ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Engineering of human H-NOX as an oxygen delivery therapeutic for prolonged admini

    SBC: OMNIOX INC            Topic: NCI

    Engineering'of'Human'H.NOX'as'an'Oxygen'Delivery'Therapeutic'for'Prolonged'Administration' ' ' Project Summary/Abstract Omniox has developed a class of tunable oxygen-delivery agents that significantly alleviate tumor hypoxia to enhance the efficacy of radiotherapy (RT). This family of therapeutic proteins, called H-NOX, can oxy ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Multiplexed Ovarian Cancer Microfluidic Tissue Microarray

    SBC: Carterra, Inc.            Topic: NCI

    Project Summary We propose an instrument system for automated, multiplexed cell- and tissue-based experiments (i.e. tissue microarrays) called the Microfluidic Flow Cell Array (MFCA). The MFCA consists of a microfluidic flow cell array integrated with an inverted fluorescent microscope, allowing the observation of 48 flow chambers simultaneously or an individual chamber at higher magnification. Th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Optoacoustic tomography system for image-guided cryotherapy of prostate cancer

    SBC: TOMOWAVE LABORATORIES, INC.            Topic: NCI

    Summary / Abstract The objective of this Phase-I SBIR project is to develop a novel transrectal optoacoustic-ultrasonic (OU) imaging system for guiding cryotherapy of prostate cancer via real-time monitoring of ice ball formation and temperature distribution within the area of healthy tissues adjacent to the rectal wall. The proposed system will be capable of (i) non-invasive monitoring of spatial ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government